Please login to the form below

Not currently logged in
Email:
Password:

UCB extends agreement with Novartis

UCB Germany has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas beyond 2011

UCB Germany, an affiliate of the Belgian biopharmaceutical company, has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas (valsartan) beyond 2011. 

The company has also negotiated rights for the hypertension treatments Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT) and will also co-market  two new oral diabeties therapies Jalra (vildagliptin Icandra and vildagliptin + metformin).

Willy Cnops, vice president  of UCB and managing director of the German operation, said in a  statement: "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

25th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics